Suppr超能文献

皮肤鳞状细胞癌的免疫治疗与全身治疗

Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma.

作者信息

Aboul-Fettouh Nader, Morse Daniel, Patel Jigar, Migden Michael R

机构信息

Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.

Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Dermatol Pract Concept. 2021 Oct 1;11(Suppl 2):e2021169S. doi: 10.5826/dpc.11S2a169S. eCollection 2021 Nov.

Abstract

Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localized therapeutic modalities, locally advanced or metastatic cSCC is a cause of significant morbidity and mortality that requires a different approach to therapy. Therapeutic attempts at treating advanced cSCC include a multi-disciplinary approach with considerations for surgery, radiation, and systemic therapies. In this review, we will discuss the various systemic therapies that have been trialed for advanced cSCC, beginning with the early cytotoxic and platinum-based agents as well as their corresponding limitations. We will then review the targeted approaches using EGFR inhibitors prior to discussing the more recent immunotherapeutics that have shown good tumor responses in this often-lethal disease.

摘要

皮肤鳞状细胞癌(cSCC)是最常被诊断出的非黑色素瘤皮肤癌之一,其全球发病率正在上升。早期和低风险的cSCC通常采用手术治疗,在某些情况下采用其他局部治疗方式,而局部晚期或转移性cSCC会导致严重的发病率和死亡率,需要采用不同的治疗方法。治疗晚期cSCC的尝试包括多学科方法,考虑手术、放疗和全身治疗。在本综述中,我们将讨论已针对晚期cSCC进行试验的各种全身治疗方法,首先是早期的细胞毒性和铂类药物及其相应的局限性。然后,在讨论最近在这种常致命疾病中显示出良好肿瘤反应的免疫疗法之前,我们将回顾使用表皮生长因子受体(EGFR)抑制剂的靶向治疗方法。

相似文献

1
Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma.
Dermatol Pract Concept. 2021 Oct 1;11(Suppl 2):e2021169S. doi: 10.5826/dpc.11S2a169S. eCollection 2021 Nov.
2
Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Stem Cell Investig. 2021 Sep 6;8:19. doi: 10.21037/sci-2020-071. eCollection 2021.
4
The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma.
Am J Clin Dermatol. 2023 Jan;24(1):25-40. doi: 10.1007/s40257-022-00742-8. Epub 2022 Dec 13.
5
Systemic therapy for advanced cutaneous squamous cell carcinoma.
Semin Cutan Med Surg. 2019 Mar 1;38(1):E67-E74. doi: 10.12788/j.sder.2019.010.
6
Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion.
Ther Adv Med Oncol. 2022 Jan 9;14:17588359211066272. doi: 10.1177/17588359211066272. eCollection 2022.
7
Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
Biomedicines. 2021 Feb 9;9(2):171. doi: 10.3390/biomedicines9020171.
8
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma.
Front Oncol. 2021 Aug 26;11:733917. doi: 10.3389/fonc.2021.733917. eCollection 2021.
9
New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma.
Expert Opin Emerg Drugs. 2023 Dec;28(2):97-106. doi: 10.1080/14728214.2023.2208345. Epub 2023 Jun 23.
10
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
Eur J Cancer. 2020 Mar;128:83-102. doi: 10.1016/j.ejca.2020.01.008. Epub 2020 Feb 26.

引用本文的文献

3
Pannexin 1 and pannexin 3 differentially regulate the cancer cell properties of cutaneous squamous cell carcinoma.
J Physiol. 2025 Aug;603(15):4409-4432. doi: 10.1113/JP286172. Epub 2024 Nov 19.
4
Unveiling the chemotherapeutic potential of two platinum(IV) complexes in skin cancer: Insights.
Curr Res Pharmacol Drug Discov. 2024 Oct 26;7:100205. doi: 10.1016/j.crphar.2024.100205. eCollection 2024.
5
The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review.
Cancers (Basel). 2024 Aug 21;16(16):2904. doi: 10.3390/cancers16162904.
6
The Role of the Neurotrophin Network in Skin Squamous Cell Cancer and the Novel Use of the Zebrafish System.
JID Innov. 2024 Jun 5;4(5):100295. doi: 10.1016/j.xjidi.2024.100295. eCollection 2024 Sep.
7
Cutaneous Squamous Cell Carcinoma: An Updated Review.
Cancers (Basel). 2024 May 8;16(10):1800. doi: 10.3390/cancers16101800.
8
Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.
Cancers (Basel). 2022 Oct 29;14(21):5325. doi: 10.3390/cancers14215325.
9
Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.
Front Oncol. 2022 Aug 2;12:919118. doi: 10.3389/fonc.2022.919118. eCollection 2022.
10
Advances in Cutaneous Squamous Cell Carcinoma Management.
Cancers (Basel). 2022 Jul 27;14(15):3653. doi: 10.3390/cancers14153653.

本文引用的文献

1
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma.
Immunother Adv. 2020 Dec 18;1(1):ltaa010. doi: 10.1093/immadv/ltaa010. eCollection 2021 Jan.
2
PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
J Cancer Res Clin Oncol. 2021 Jun;147(6):1803-1811. doi: 10.1007/s00432-020-03458-6. Epub 2020 Nov 18.
3
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease.
Physiol Rev. 2016 Jul;96(3):1025-1069. doi: 10.1152/physrev.00030.2015.
5
6
9
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.
Drugs Context. 2019 Dec 19;8:212611. doi: 10.7573/dic.212611. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验